About Bioptimus
Bioptimus is a Healthcare company based in Paris (France) founded in 2024 by Jean-Philippe Vert, Felipe Llinares-Lopez, Rodolphe Jenatton, Zelda Mariet, David C, and Eric Durand. It operates as an AI foundation models are developed for biological research integration. Bioptimus has raised $76 million across 2 funding rounds from investors including Owkin, Bpifrance and Sunrise. Its website bioptimus.com draws about 13 thousand monthly visits. Bioptimus offers products and services including H-optimus-1 and M-optimus. Its focus areas include HealthTech, Life Sciences Tech, Research & Development and Drug Discovery. Its competitors include Formation Bio, Owkin, BigHat, Benchsci and Predictive Oncology and 4 more; 9 of its 9 listed competitors have raised funding.
Company details
Bioptimus was founded in 2024 in Paris, France, within the artificial intelligence sector focused on biology. Multi-scale biological data, ranging from molecules to tissues, is integrated through foundation models. New insights are generated for biomedicine applications. Operations center on accelerating research discoveries across related scientific domains. The approach supports advancements in therapeutic and innovative biological processes.
- Headquarters Paris, France
- Founders Jean-Philippe Vert, Felipe Llinares-Lopez, Rodolphe Jenatton, Zelda Mariet, David C, Eric Durand
- SectorsHealthcare
- Website bioptimus.com
- Social LinkedIn X
- Total Equity Funding$76M (USD)
in 2 rounds
- Latest Funding Round$41M (USD), Series A
Jan 2025
- InvestorsOwkin
& 16 more
Products & Services of Bioptimus
Bioptimus offers a comprehensive portfolio of products and services, including H-optimus-1 and M-optimus.
AI model for transforming biology and fueling scientific discoveries
AI model for accelerating innovations in biomedicine and beyond
Funding Insights of Bioptimus
Bioptimus has successfully raised a total of $76M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $41 million completed in January 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $76M
- Total Rounds 2
- Last Round Series A — $41M
- First Round $35M
(Feb 2024)
- Investors Count 17
All 2 funding rounds of Bioptimus with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2025 | $41M | Series A | – | Cathay Innovation | |
| Feb 2024 | $35M | Seed | – | Sofinnova Partners, Bpifrance |
17 investors in total: 14 institutional and 3 angel.
Investors in Bioptimus
Bioptimus has secured backing from 17 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include Owkin, Bpifrance and Sunrise.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital investments are made in technology startups through a global ecosystem. | – | cathayinnovation.com | - | |
Sofinnova Partners is focused on life sciences and healthcare investments. | – | sofinnovapartners.com | Paris, France | |
Capital is provided to firms for growth, buyouts, and acquisitions. | 2001 | anderapartners.com | Paris, France | |
Venture capital funding is provided for technology and healthcare companies. | – | hitachi-ventures.com | Munich, Germany | |
Early investments in science-focused startups are made by BOOM Capital. | – | boomcap.co | - | |
Early-stage startups across France are invested in by Frst Capital. | – | frst.vc | Paris, France | |
Investments are made in early-stage tech startups across multiple sectors. | – | headline.com | San Francisco, United States | |
Investments in early-stage startups are focused on by Hummingbird Ventures. | – | hummingbird.vc | London, United Kingdom | |
Venture capital investments are directed toward multiple sectors. | – | njfcapital.com | London, United Kingdom | |
- | – | topharvestcap.com | - |
Investor details for Bioptimus
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Bioptimus
7 people are tracked at Bioptimus (7 in leadership).
| Name | Role | Group |
|---|---|---|
Jean-Philippe Vert | Co-Founder | Leadership |
Felipe Llinares-Lopez | Co-Founder | Leadership |
Rodolphe Jenatton | Co-Founder | Leadership |
Zelda Mariet | Co-Founder | Leadership |
David C | Co-Founder | Leadership |
Eric Durand | Co-Founder | Leadership |
Mathilda Strom | Founding Chief Operating Officer | Leadership |
Complete people profiles for Bioptimus
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Bioptimus
3 dated milestones of Bioptimus across 1 years, from founding to its latest funding, stage changes and deals.
- Founded Bioptimus is founded.
- Funding First funding round of $35.0M.
- Funding Latest funding round, Series A, of $41.0M.
Competitors of Bioptimus
Bioptimus has 9 listed competitors in our database, 9 of them funded. They include Formation Bio, Owkin, BigHat, Benchsci and Predictive Oncology, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| formation.bio | 2016 | New York, United States | $608.25M | – | AI-powered drug discovery platform for various diseases | |
| owkin.com | 2016 | Paris, France | $321.1M | 47 | An agentic AI platform is developed for biomedical research insights. | |
| bighatbio.com | 2019 | San Carlos, United States | $148.41M | – | Antibody therapies are developed through machine learning and synthetic biology. | |
| benchsci.com | 2015 | Toronto, Canada | $157.73M | – | AI platform used for extracting antibody data from scientific papers. | |
| predictive-oncology.com | 2002 | Eagan, United States | $43M | 31 | AI-based platform for cancer diagnostics and precision medicine is utilized. | |
| iambic.ai | 2019 | San Diego, United States | $206.23M | 50 | AI-driven drug discovery platform for the treatment of cancer | |
| absci.com | 2011 | Vancouver, United States | $227.56M | 256 | AI-based technology is used for recombinant protein production in therapeutics. | |
| xtalpi.com | 2014 | Cambridge, United States | $784.8M | 33 | AI-driven crystal structure prediction for pharmaceutical development is offered. | |
| verisimlife.com | 2017 | San Francisco, United States | $21.4M | 13 | AI-based biosimulation models are used for drug development predictions. |
Detailed competitors of Bioptimus
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Bioptimus
The website of Bioptimus (bioptimus.com) receives about 12.6K visits a month.
- Monthly visits12.6K
▼ 12.4% vs previous month
Websites whose visitors overlap most with Bioptimus. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| owkin.com | 100% | 42.6K | #724,166 | View details | |
| cfnews.net | 89% | – | #250,173 | View details |
Top companies in Life Sciences Platforms & Tools
10 companies that operate in the same segment as Bioptimus (Life Sciences Platforms & Tools), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | – | – | |
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | – | 1,111 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.34 B | USD 301.49 M | 1,372 | |
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Biological reagents and antibodies are developed for life science research. | 1998 | Cambridge, Cambridgeshire, United Kingdom | USD 78.8 M | – | – | |
Electron microscopy services and microanalysis instruments are provided. | 1956 | Waltham, Massachusetts, United States | – | USD 44.56 B | 125,000 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
A platform for sharing and accessing academic research papers is provided. | 2008 | San Francisco, California, United States | USD 58.4 M | – | – | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Bioptimus
Complete news archive for Bioptimus
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Bioptimus
Bioptimus was founded in 2024.
Bioptimus is headquartered in Paris, France.
Bioptimus is a funded company, having raised a total of $76M across 2 funding rounds to date. The company's 1st funding round was a Seed of $35M, raised on Feb 2024.
Bioptimus was founded in 2024 in Paris, France, within the artificial intelligence sector focused on biology. Multi-scale biological data, ranging from molecules to tissues, is integrated through foundation models. New insights are generated for biomedicine applications. Operations center on accelerating research discoveries across related scientific domains. The approach supports advancements in therapeutic and innovative biological processes.
Bioptimus's top competitors include Owkin, Formation Bio and XtalPi.
Bioptimus offers H-optimus-1 and M-optimus.
Bioptimus has 17 investors. Key investors include Owkin, Bpifrance, Sunrise, Andera Partners, and Cathay Innovation.